GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Malin Corporation PLC (DUB:MLC) » Definitions » ROE % Adjusted to Book Value

Malin (DUB:MLC) ROE % Adjusted to Book Value : 0.00% (As of Dec. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Malin ROE % Adjusted to Book Value?

Malin's ROE % for the quarter that ended in Dec. 2024 was 0.00%. Malin's PB Ratio for the quarter that ended in Dec. 2024 was 0.84. Malin's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 was 0.00%.


Malin ROE % Adjusted to Book Value Historical Data

The historical data trend for Malin's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Malin ROE % Adjusted to Book Value Chart

Malin Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 54.29 13.30 5.84 - -

Malin Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.18 1.25 -2.74 - -

Competitive Comparison of Malin's ROE % Adjusted to Book Value

For the Drug Manufacturers - Specialty & Generic subindustry, Malin's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Malin's ROE % Adjusted to Book Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Malin's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Malin's ROE % Adjusted to Book Value falls into.


;
;

Malin ROE % Adjusted to Book Value Calculation

Malin's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / 0.84
=0.00%

Malin's ROE % Adjusted to Book Value for the quarter that ended in Dec. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=0.00% / 0.84
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Malin ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Malin's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Malin Business Description

Traded in Other Exchanges
N/A
Address
50 Richmond Street South, The Lennox Building, Dublin, IRL, D02 FK02
Malin Corporation PLC is a life sciences company. Its investee companies are in science and discovery, clinical and commercial sectors. The company's approach is to create shareholder value through the selective long-term application of capital and operational expertise to private, pre-trade sale operating businesses in the life sciences industry. The company derives all of its revenue from its subsidiary. The company focuses on oncology, immunology, and genetic diseases where it believes that life science and healthcare technologies will deliver transformative treatments for patients.

Malin Headlines

No Headlines